Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

BetaProtect First-in-man beta-cell regeneration for causal type 2 diabetes therapy

Coordinator
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH, Germany
Runs
1 November 2026 to 30 April 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101332721

What the project is doing

In the project's own words, from its summary on CORDIS.

More than 589 million people worldwide suffer from diabetes (IDF atlas 11th edition). Currently, none of the pharmacological therapies can stop disease progression, which leads to devastating micro- and macrovascular complications and a steady increase in patient numbers. Prediabetic individuals develop type 2 diabetes (T2D) when insulin-producing beta-cells in the pancreas become insulin resistant, lose their function and die.

Importantly, beta-cells not only produce insulin but also are critically dependent on insulin signaling for their function, survival and compensation upon increased metabolic needs due to gluco/lipotoxicity and insulin resistance. In a breakthrough discovery, we have previously identified a novel and druggable insulin inhibitory receptor (in short: inceptor). Genetic or pharmacological inceptor blockade allows insulin sensitization to enhance beta-cell function, survival, and regeneration, and as such, allows for the first time to revert diabetes progression in T2D mouse models.

Based on this novel therapeutic target and encouraging preclinical findings, we aim to develop a transformative, disease-modifying therapy for diabetes that goes beyond the symptomatic treatments currently available. The goal of this ERC Proof-of-Concept (PoC) grant is to provide financial, business, developmental and regulatory preparedness for the new spin-off company Viacure Therapeutics GmbH, which plans to make the transition from basic research to preclinical and clinical development to implement first-in-class beta-cell regeneration therapy in the clinic, as a first causative treatment for people living with T2D.

Who is involved

OrganisationCityCountryRole
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyCoordinator
Viacure Therapeutics GmbHRadebergGermanyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI